BRPI0921692A2 - composto carbamato ou o sal do mesmo - Google Patents
composto carbamato ou o sal do mesmoInfo
- Publication number
- BRPI0921692A2 BRPI0921692A2 BRPI0921692-8A BRPI0921692A BRPI0921692A2 BR PI0921692 A2 BRPI0921692 A2 BR PI0921692A2 BR PI0921692 A BRPI0921692 A BR PI0921692A BR PI0921692 A2 BRPI0921692 A2 BR PI0921692A2
- Authority
- BR
- Brazil
- Prior art keywords
- faah
- inhibitory activity
- action
- ylcarbonyl
- piperazine
- Prior art date
Links
- -1 carbamate compound Chemical class 0.000 title abstract 5
- 150000003839 salts Chemical class 0.000 title 1
- 102100027297 Fatty acid 2-hydroxylase Human genes 0.000 abstract 5
- 101000937693 Homo sapiens Fatty acid 2-hydroxylase Proteins 0.000 abstract 5
- 101000918494 Homo sapiens Fatty-acid amide hydrolase 1 Proteins 0.000 abstract 5
- 230000002401 inhibitory effect Effects 0.000 abstract 3
- 208000005615 Interstitial Cystitis Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 206010069918 Bacterial prostatitis Diseases 0.000 abstract 1
- 206010005063 Bladder pain Diseases 0.000 abstract 1
- 208000000450 Pelvic Pain Diseases 0.000 abstract 1
- 206010062225 Urinary tract pain Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000000202 analgesic effect Effects 0.000 abstract 1
- 230000002686 anti-diuretic effect Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 abstract 1
- 206010029446 nocturia Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000004193 piperazinyl group Chemical group 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Anesthesiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2008285466 | 2008-11-06 | ||
| JP2008-285466 | 2008-11-06 | ||
| PCT/JP2009/068902 WO2010053120A1 (ja) | 2008-11-06 | 2009-11-05 | カルバメート化合物又はその塩 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0921692A2 true BRPI0921692A2 (pt) | 2018-06-26 |
Family
ID=42152927
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0921692-8A BRPI0921692A2 (pt) | 2008-11-06 | 2009-11-05 | composto carbamato ou o sal do mesmo |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20110212973A1 (pt) |
| EP (1) | EP2351749A1 (pt) |
| JP (1) | JPWO2010053120A1 (pt) |
| KR (1) | KR20110091508A (pt) |
| CN (1) | CN102209718A (pt) |
| AU (1) | AU2009312032A1 (pt) |
| BR (1) | BRPI0921692A2 (pt) |
| CA (1) | CA2741500A1 (pt) |
| IL (1) | IL212403A0 (pt) |
| MX (1) | MX2011004704A (pt) |
| RU (1) | RU2011117927A (pt) |
| TW (1) | TW201031652A (pt) |
| WO (1) | WO2010053120A1 (pt) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011026241A1 (en) * | 2009-09-04 | 2011-03-10 | Zalicus Pharmaceuticals Ltd. | Substituted heterocyclic derivatives for the treatment of pain and epilepsy |
| CA2785284A1 (en) | 2009-12-25 | 2011-06-30 | Tomoyuki Kamino | Novel aryl urea derivative |
| US20130150346A1 (en) | 2010-01-08 | 2013-06-13 | Quest Ventures Ltd. | Use of FAAH Inhibitors for Treating Parkinson's Disease and Restless Legs Syndrome |
| US20130224151A1 (en) | 2010-03-31 | 2013-08-29 | United States Of America | Use of FAAH Inhibitors for Treating Abdominal, Visceral and Pelvic Pain |
| JP2013147430A (ja) * | 2010-04-28 | 2013-08-01 | Astellas Pharma Inc | 夜間頻尿の予防又は治療剤 |
| TW201206440A (en) * | 2010-04-28 | 2012-02-16 | Astellas Pharma Inc | Prophylactic or therapeutic agent for diseases associated with pains in urinary organs |
| EP2961403A4 (en) | 2013-03-01 | 2016-11-30 | Zalicus Pharmaceuticals Ltd | HETEROCYCLIC INHIBITORS OF SODIUM CHANNEL |
| RU2683261C2 (ru) * | 2014-05-28 | 2019-03-27 | Астеллас Фарма Инк. | Производное пиридина |
| AR102849A1 (es) * | 2015-03-09 | 2017-03-29 | Astellas Pharma Inc | Compuesto de piridina bicíclica |
| CN114478359B (zh) * | 2022-03-17 | 2023-09-29 | 河南大学 | 氨基甲酸酯类trpv1拮抗/faah抑制双靶点药物及其制备方法和应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6949574B2 (en) | 2002-02-08 | 2005-09-27 | Bristol-Myers Squibb Company | (Oxime)carbamoyl fatty acid amide hydrolase inhibitors |
| US7176201B2 (en) | 2002-10-07 | 2007-02-13 | The Regents Of The University Of California | Modulation of anxiety through blockade of anandamide hydrolysis |
| CA2598294C (en) | 2005-02-17 | 2011-10-18 | Astellas Pharma Inc. | Pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate derivative |
| WO2008023720A1 (fr) | 2006-08-23 | 2008-02-28 | Astellas Pharma Inc. | COMPOSÉ D'URÉE OU SEL DUDIT COMPOSé |
-
2009
- 2009-11-05 CA CA2741500A patent/CA2741500A1/en not_active Abandoned
- 2009-11-05 EP EP09824819A patent/EP2351749A1/en not_active Withdrawn
- 2009-11-05 BR BRPI0921692-8A patent/BRPI0921692A2/pt not_active IP Right Cessation
- 2009-11-05 US US13/126,980 patent/US20110212973A1/en not_active Abandoned
- 2009-11-05 WO PCT/JP2009/068902 patent/WO2010053120A1/ja active Application Filing
- 2009-11-05 CN CN2009801444505A patent/CN102209718A/zh active Pending
- 2009-11-05 MX MX2011004704A patent/MX2011004704A/es not_active Application Discontinuation
- 2009-11-05 TW TW098137612A patent/TW201031652A/zh unknown
- 2009-11-05 KR KR1020117010369A patent/KR20110091508A/ko not_active Application Discontinuation
- 2009-11-05 JP JP2010536783A patent/JPWO2010053120A1/ja not_active Withdrawn
- 2009-11-05 RU RU2011117927/04A patent/RU2011117927A/ru unknown
- 2009-11-05 AU AU2009312032A patent/AU2009312032A1/en not_active Abandoned
-
2011
- 2011-04-17 IL IL212403A patent/IL212403A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2011117927A (ru) | 2012-12-20 |
| US20110212973A1 (en) | 2011-09-01 |
| IL212403A0 (en) | 2011-06-30 |
| KR20110091508A (ko) | 2011-08-11 |
| MX2011004704A (es) | 2011-05-30 |
| EP2351749A1 (en) | 2011-08-03 |
| JPWO2010053120A1 (ja) | 2012-04-05 |
| WO2010053120A1 (ja) | 2010-05-14 |
| CN102209718A (zh) | 2011-10-05 |
| TW201031652A (en) | 2010-09-01 |
| AU2009312032A1 (en) | 2010-05-14 |
| CA2741500A1 (en) | 2010-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0921692A2 (pt) | composto carbamato ou o sal do mesmo | |
| TW200640864A (en) | Pyridyl non-aromatic nitrogenated heterocyclic-1-carboxylate ester derivative | |
| BR112013031098A2 (pt) | halogeno-alquil-1,3 oxazinas como inibidores de bace1 e/ou bace2 | |
| WO2011014255A8 (en) | Treatment of crohn's disease with laquinimod | |
| NO20083032L (no) | Anvendelse av benzofuserte heterocykliske sulfamidderivater for behandling av mani og bipolar forstyrrelse | |
| AR074471A1 (es) | Compuesto 5(5-(2-(3-aminopropoxi) - 6 - metoxifenil) -1h- pirazol-3- ilamino ) pirazin -2-carbonitrilo , composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para inhibir chk1 y para tratar cancer | |
| EA201070121A1 (ru) | Лекарственная форма, содержащая слитый белок glp-1-fc | |
| HRP20120144T1 (en) | Therapeutic uses of compounds having combined sert, 5-ht3 and 5-ht1a activity | |
| WO2008148074A3 (en) | Inhibitors of mtor and methods of treatment using same | |
| BR112014006763A2 (pt) | n-(3-(2-amino-6,6-difluoro-4,4a,5,6,7,7a-hexa-hidro-ciclopenta[e][1,3]oxazin-4-il)-fenil)-amidas como inibidores de bace1 | |
| FR2929511B1 (fr) | Nouveau principe actif stimulant la proliferation et/ou l'activite des fibroblastes. | |
| EA200970435A1 (ru) | Лечение общих расстройств развития | |
| IL192100A0 (en) | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain | |
| DOP2005000039A (es) | Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)- piperidin-1-il]-(4-bomo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos | |
| ATE540690T1 (de) | Insulinkombinationen | |
| WO2007117560A3 (en) | Piperidine and morpholine renin inhibitors | |
| CY1110336T1 (el) | Χρηση της αλλοπουρινολης για τη θεραπεια της παλαμοπελματικης ερυθροδυσαισθησιας | |
| EP3858385A3 (en) | Polymer-conjugated metap2 inhibitors, and therapeutic methods of use thereof | |
| WO2006108682A3 (en) | Substances and pharmaceutical compositions for the inhibition of glyoxalases and their use as anti-fungal agents | |
| DK1569896T3 (da) | Tetrahydronaphthalenderivater | |
| WO2007117559A8 (en) | Renin inhibitors | |
| ATE371641T1 (de) | Hydroxy-tetrahydro-naphtalenylharnstoff-derivat | |
| WO2006102899A3 (en) | Oxaprozin or closely related compound for the treatment and prevention of | |
| EA200800071A1 (ru) | Производные бензофуранила как ингибиторы 5-нт6-рецептора | |
| BR112012026876A2 (pt) | agente para prevenção ou tratamento de doenças acompanhadas por dor urinária |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2478 DE 03-07-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |